Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

CME vs JPM

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
CME
CME Group Inc.

Financial - Data & Stock Exchanges

Financial ServicesNASDAQ • US
Market Cap$104.61B
5Y Perf.+57.9%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$849.03B
5Y Perf.+223.6%

CME vs JPM — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
CME logoCME
JPM logoJPM
IndustryFinancial - Data & Stock ExchangesBanks - Diversified
Market Cap$104.61B$849.03B
Revenue (TTM)$6.52B$270.79B
Net Income (TTM)$4.24B$58.03B
Gross Margin86.1%58.6%
Operating Margin64.9%27.7%
Forward P/E23.6x14.2x
Total Debt$3.76B$751.15B
Cash & Equiv.$4.42B$469.32B

CME vs JPMLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

CME
JPM
StockMay 20May 26Return
CME Group Inc. (CME)100157.9+57.9%
JPMorgan Chase & Co. (JPM)100323.6+223.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: CME vs JPM

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CME leads in 4 of 7 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. JPMorgan Chase & Co. is the stronger pick specifically for growth and revenue expansion and valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
CME
CME Group Inc.
The Banking Pick

CME carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.

  • Dividend streak 6 yrs, beta -0.30, yield 3.8%
  • Lower volatility, beta -0.30, Low D/E 13.1%, current ratio 92.97x
  • Beta -0.30, yield 3.8%, current ratio 92.97x
Best for: income & stability and sleep-well-at-night
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is growth exposure and long-term compounding.

  • Rev growth 14.6%, EPS growth 21.7%
  • 471.7% 10Y total return vs CME's 291.2%
  • PEG 1.09 vs CME's 1.72
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthJPM logoJPM14.6% NII/revenue growth vs CME's 6.4%
ValueJPM logoJPMLower P/E (14.2x vs 23.6x), PEG 1.09 vs 1.72
Quality / MarginsCME logoCMEEfficiency ratio 0.2% vs JPM's 0.3% (lower = leaner)
Stability / SafetyCME logoCMELower D/E ratio (13.1% vs 217.9%)
DividendsCME logoCME3.8% yield, 6-year raise streak, vs JPM's 1.6%
Momentum (1Y)JPM logoJPM+28.7% vs CME's +5.9%
Efficiency (ROA)CME logoCMEEfficiency ratio 0.2% vs JPM's 0.3%

CME vs JPM — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

CMECME Group Inc.
FY 2025
clearing and transaction fees
81.0%$5.3B
MarketData
12.3%$803M
OtherRevenue
6.7%$436M
JPMJPMorgan Chase & Co.
FY 2024
Consumer & Community Banking
40.3%$71.5B
Commercial And Investment Bank
39.5%$70.1B
Asset and Wealth Management Segment
12.2%$21.6B
Segment Reporting, Reconciling Item, Corporate Nonsegment
9.8%$17.4B
Segment Reconciling Items
-1.7%$-3,037,000,000

CME vs JPM — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLCMELAGGINGJPM

Income & Cash Flow (Last 12 Months)

CME leads this category, winning 5 of 5 comparable metrics.

JPM is the larger business by revenue, generating $270.8B annually — 41.5x CME's $6.5B. CME is the more profitable business, keeping 62.0% of every revenue dollar as net income compared to JPM's 21.6%.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
RevenueTrailing 12 months$6.5B$270.8B
EBITDAEarnings before interest/tax$4.7B$81.3B
Net IncomeAfter-tax profit$4.2B$58.0B
Free Cash FlowCash after capex$4.4B-$119.7B
Gross MarginGross profit ÷ Revenue+86.1%+58.6%
Operating MarginEBIT ÷ Revenue+64.9%+27.7%
Net MarginNet income ÷ Revenue+62.0%+21.6%
FCF MarginFCF ÷ Revenue+64.3%-15.5%
Rev. Growth (YoY)Latest quarter vs prior year
EPS Growth (YoY)Latest quarter vs prior year+21.4%+16.0%
CME leads this category, winning 5 of 5 comparable metrics.

Valuation Metrics

JPM leads this category, winning 6 of 6 comparable metrics.

At 15.9x trailing earnings, JPM trades at a 38% valuation discount to CME's 25.8x P/E. Adjusting for growth (PEG ratio), JPM offers better value at 1.23x vs CME's 1.88x — a lower PEG means you pay less per unit of expected earnings growth.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
Market CapShares × price$104.6B$849.0B
Enterprise ValueMkt cap + debt − cash$103.9B$1.13T
Trailing P/EPrice ÷ TTM EPS25.84x15.94x
Forward P/EPrice ÷ next-FY EPS est.23.61x14.17x
PEG RatioP/E ÷ EPS growth rate1.88x1.23x
EV / EBITDAEnterprise value multiple23.08x13.62x
Price / SalesMarket cap ÷ Revenue16.04x3.14x
Price / BookPrice ÷ Book value/share3.62x2.63x
Price / FCFMarket cap ÷ FCF24.95x
JPM leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

CME leads this category, winning 6 of 8 comparable metrics.

JPM delivers a 16.1% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $15 for CME. CME carries lower financial leverage with a 0.13x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.18x.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
ROE (TTM)Return on equity+15.3%+16.1%
ROA (TTM)Return on assets+2.2%+1.3%
ROICReturn on invested capital+10.2%+5.4%
ROCEReturn on capital employed+3.6%+8.2%
Piotroski ScoreFundamental quality 0–955
Debt / EquityFinancial leverage0.13x2.18x
Net DebtTotal debt minus cash-$666M$281.8B
Cash & Equiv.Liquid assets$4.4B$469.3B
Total DebtShort + long-term debt$3.8B$751.1B
Interest CoverageEBIT ÷ Interest expense41.55x0.74x
CME leads this category, winning 6 of 8 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,034 today (with dividends reinvested), compared to $16,408 for CME. Over the past 12 months, JPM leads with a +28.7% total return vs CME's +5.9%. The 3-year compound annual growth rate (CAGR) favors JPM at 34.0% vs CME's 19.9% — a key indicator of consistent wealth creation.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
YTD ReturnYear-to-date+9.7%-2.3%
1-Year ReturnPast 12 months+5.9%+28.7%
3-Year ReturnCumulative with dividends+72.2%+140.8%
5-Year ReturnCumulative with dividends+64.1%+110.3%
10-Year ReturnCumulative with dividends+291.2%+471.7%
CAGR (3Y)Annualised 3-year return+19.9%+34.0%
JPM leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CME and JPM each lead in 1 of 2 comparable metrics.

CME is the less volatile stock with a -0.30 beta — it tends to amplify market swings less than JPM's 1.00 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. JPM currently trades 93.4% from its 52-week high vs CME's 87.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
Beta (5Y)Sensitivity to S&P 500-0.30x1.00x
52-Week HighHighest price in past year$329.16$337.25
52-Week LowLowest price in past year$257.17$248.83
% of 52W HighCurrent price vs 52-week peak+87.6%+93.4%
RSI (14)Momentum oscillator 0–10041.753.4
Avg Volume (50D)Average daily shares traded2.2M8.4M
Evenly matched — CME and JPM each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CME and JPM each lead in 1 of 2 comparable metrics.

Wall Street rates CME as "Hold" and JPM as "Buy". Consensus price targets imply 11.1% upside for CME (target: $320) vs 7.6% for JPM (target: $339). For income investors, CME offers the higher dividend yield at 3.79% vs JPM's 1.63%.

MetricCME logoCMECME Group Inc.JPM logoJPMJPMorgan Chase & …
Analyst RatingConsensus buy/hold/sellHoldBuy
Price TargetConsensus 12-month target$320.25$338.78
# AnalystsCovering analysts3561
Dividend YieldAnnual dividend ÷ price+3.8%+1.6%
Dividend StreakConsecutive years of raises614
Dividend / ShareAnnual DPS$10.92$5.13
Buyback YieldShare repurchases ÷ mkt cap+0.3%+3.4%
Evenly matched — CME and JPM each lead in 1 of 2 comparable metrics.
Key Takeaway

CME leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). JPM leads in 2 (Valuation Metrics, Total Returns). 2 tied.

Best OverallCME Group Inc. (CME)Leads 2 of 6 categories
Loading custom metrics...

CME vs JPM: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is CME or JPM a better buy right now?

For growth investors, JPMorgan Chase & Co.

(JPM) is the stronger pick with 14. 6% revenue growth year-over-year, versus 6. 4% for CME Group Inc. (CME). JPMorgan Chase & Co. (JPM) offers the better valuation at 15. 9x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate JPMorgan Chase & Co. (JPM) a "Buy" — based on 61 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — CME or JPM?

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 15. 9x versus CME Group Inc. at 25. 8x. On forward P/E, JPMorgan Chase & Co. is actually cheaper at 14. 2x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 1. 09x versus CME Group Inc. 's 1. 72x — a reasonable growth-adjusted valuation.

03

Which is the better long-term investment — CME or JPM?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +110. 3%, compared to +64. 1% for CME Group Inc. (CME). Over 10 years, the gap is even starker: JPM returned +471. 7% versus CME's +291. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — CME or JPM?

By beta (market sensitivity over 5 years), CME Group Inc.

(CME) is the lower-risk stock at -0. 30β versus JPMorgan Chase & Co. 's 1. 00β — meaning JPM is approximately -430% more volatile than CME relative to the S&P 500. On balance sheet safety, CME Group Inc. (CME) carries a lower debt/equity ratio of 13% versus 2% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — CME or JPM?

By revenue growth (latest reported year), JPMorgan Chase & Co.

(JPM) is pulling ahead at 14. 6% versus 6. 4% for CME Group Inc. (CME). On earnings-per-share growth, the picture is similar: JPMorgan Chase & Co. grew EPS 21. 7% year-over-year, compared to 15. 4% for CME Group Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — CME or JPM?

CME Group Inc.

(CME) is the more profitable company, earning 62. 0% net margin versus 21. 6% for JPMorgan Chase & Co. — meaning it keeps 62. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CME leads at 64. 9% versus 27. 7% for JPM. At the gross margin level — before operating expenses — CME leads at 86. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is CME or JPM more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 1. 09x versus CME Group Inc. 's 1. 72x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, JPMorgan Chase & Co. (JPM) trades at 14. 2x forward P/E versus 23. 6x for CME Group Inc. — 9. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CME: 11. 1% to $320. 25.

08

Which pays a better dividend — CME or JPM?

All stocks in this comparison pay dividends.

CME Group Inc. (CME) offers the highest yield at 3. 8%, versus 1. 6% for JPMorgan Chase & Co. (JPM).

09

Is CME or JPM better for a retirement portfolio?

For long-horizon retirement investors, CME Group Inc.

(CME) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 30), 3. 8% yield, +291. 2% 10Y return). Both have compounded well over 10 years (CME: +291. 2%, JPM: +471. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between CME and JPM?

Both stocks operate in the Financial Services sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: CME is a mid-cap income-oriented stock; JPM is a large-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

CME

Dividend Mega-Cap Quality

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 37%
Run This Screen
Stocks Like

JPM

Dividend Mega-Cap Quality

  • Sector: Financial Services
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 12%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform CME and JPM on the metrics below

Revenue Growth>
%
(CME: 6.4% · JPM: 14.6%)
Net Margin>
%
(CME: 62.0% · JPM: 21.6%)
P/E Ratio<
x
(CME: 25.8x · JPM: 15.9x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.